● PRNewsWireNov 5, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands
October agreement advances the U.S. customer program to approximately $5.1 million in committed base services JERUSALEM, Nov. 5, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Compan…
● PRNewsWireOct 20, 2026 · 08:49 ETCOMPANY'S OWN WORDS
Scinai CEO Updates Shareholders on CDMO Growth and Extended Runway Following Completed Financing
Management estimates operating runway to late 2027, with potential extension into the third quarter of 2028 as later project phases under the recently announced CDMO agreement are activated and delivered JERUSALEM, Oct. …
● PRNewsWireOct 16, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement
JERUSALEM, Oct. 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and manufacturing organization ("CD…
● PRNewsWireOct 14, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement
JERUSALEM, October 14, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and manufacturing organization (…
● PRNewsWireOct 13, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement
Committed Customer Orders¹ reach approximately $7.6 million, up approximately 300% from $1.9 million at year-end 2025 Agreement with a U.S. based, Nasdaq-listed biopharmaceutical company supports development activity in …
● PRNewsWireSep 21, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement
Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter is closed JERUSALEM, Sept. 21, 2026 /PRNewswire/ -- Scinai I…
● PRNewsWireSep 8, 2026 · 09:18 ETCOMPANY'S OWN WORDS
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business
Following the conclusion of the PinCell option and license arrangements, Scinai concentrates resources on its NanoAb platform and CDMO commercial execution, without taking on additional PC111 funding commitments JERUSALE…
Article counts from the last market-wide feed page, across every symbol we track and not just SCNI · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.